2042 related articles for article (PubMed ID: 21716157)
1. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
2. My approach to and thoughts on the typing of ovarian carcinomas.
McCluggage WG
J Clin Pathol; 2008 Feb; 61(2):152-63. PubMed ID: 17704261
[TBL] [Abstract][Full Text] [Related]
3. Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin.
Morency E; Leitao MM; Soslow RA
Int J Gynecol Pathol; 2016 May; 35(3):222-9. PubMed ID: 26630225
[TBL] [Abstract][Full Text] [Related]
4. Histological classification of ovarian cancer.
Kaku T; Ogawa S; Kawano Y; Ohishi Y; Kobayashi H; Hirakawa T; Nakano H
Med Electron Microsc; 2003 Mar; 36(1):9-17. PubMed ID: 12658347
[TBL] [Abstract][Full Text] [Related]
5. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
6. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
7. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters.
Lin CK; Chao TK; Yu CP; Yu MH; Jin JS
APMIS; 2009 Mar; 117(3):162-75. PubMed ID: 19245589
[TBL] [Abstract][Full Text] [Related]
8. Differences in tumor type in low-stage versus high-stage ovarian carcinomas.
Köbel M; Kalloger SE; Huntsman DG; Santos JL; Swenerton KD; Seidman JD; Gilks CB;
Int J Gynecol Pathol; 2010 May; 29(3):203-11. PubMed ID: 20407318
[TBL] [Abstract][Full Text] [Related]
9. [Preliminary study on the relationship between tubal intraepithelial carcinoma of the fimbria and pelvic high-grade serous carcinoma].
Liang Y; Chen XD; Lü BJ; Zhou CY; Zhang XF; Shi HY
Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):724-8. PubMed ID: 22321343
[TBL] [Abstract][Full Text] [Related]
10. [Ovarian cancer--modern approach to its origin and histogenesis].
Nowak-Markwitz E; Spaczyński M
Ginekol Pol; 2012 Jun; 83(6):454-7. PubMed ID: 22880466
[TBL] [Abstract][Full Text] [Related]
11. Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?
Moss EL; Evans T; Pearmain P; Askew S; Singh K; Chan KK; Ganesan R; Hirschowitz L
Int J Gynecol Cancer; 2015 Sep; 25(7):1201-7. PubMed ID: 26035124
[TBL] [Abstract][Full Text] [Related]
12. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
13. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
Sieh W; Köbel M; Longacre TA; Bowtell DD; deFazio A; Goodman MT; Høgdall E; Deen S; Wentzensen N; Moysich KB; Brenton JD; Clarke BA; Menon U; Gilks CB; Kim A; Madore J; Fereday S; George J; Galletta L; Lurie G; Wilkens LR; Carney ME; Thompson PJ; Matsuno RK; Kjær SK; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Vierkant RA; Cunningham JM; Brinton LA; Yang HP; Sherman ME; García-Closas M; Lissowska J; Odunsi K; Morrison C; Lele S; Bshara W; Sucheston L; Jimenez-Linan M; Driver K; Alsop J; Mack M; McGuire V; Rothstein JH; Rosen BP; Bernardini MQ; Mackay H; Oza A; Wozniak EL; Benjamin E; Gentry-Maharaj A; Gayther SA; Tinker AV; Prentice LM; Chow C; Anglesio MS; Johnatty SE; Chenevix-Trench G; Whittemore AS; Pharoah PD; Goode EL; Huntsman DG; Ramus SJ
Lancet Oncol; 2013 Aug; 14(9):853-62. PubMed ID: 23845225
[TBL] [Abstract][Full Text] [Related]
14. Utility of hepatocyte nuclear factor-1β as a diagnostic marker in ovarian carcinomas with clear cells.
Kao YC; Lin MC; Lin WC; Jeng YM; Mao TL
Histopathology; 2012 Nov; 61(5):760-8. PubMed ID: 22747504
[TBL] [Abstract][Full Text] [Related]
15. Origins and molecular pathology of ovarian cancer.
Bell DA
Mod Pathol; 2005 Feb; 18 Suppl 2():S19-32. PubMed ID: 15761464
[TBL] [Abstract][Full Text] [Related]
16. Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates.
Gurung A; Hung T; Morin J; Gilks CB
Histopathology; 2013 Jan; 62(1):59-70. PubMed ID: 23240670
[TBL] [Abstract][Full Text] [Related]
17. Histologic subtypes of ovarian carcinoma: an overview.
Soslow RA
Int J Gynecol Pathol; 2008 Apr; 27(2):161-74. PubMed ID: 18317227
[TBL] [Abstract][Full Text] [Related]
18. Are all pelvic (nonuterine) serous carcinomas of tubal origin?
Przybycin CG; Kurman RJ; Ronnett BM; Shih IeM; Vang R
Am J Surg Pathol; 2010 Oct; 34(10):1407-16. PubMed ID: 20861711
[TBL] [Abstract][Full Text] [Related]
19. Transitional cell-like morphology in ovarian endometrioid carcinoma: morphologic, immunohistochemical, and behavioral features distinguishing it from high-grade serous carcinoma.
Karnezis AN; Aysal A; Zaloudek CJ; Rabban JT
Am J Surg Pathol; 2013 Jan; 37(1):24-37. PubMed ID: 23108017
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
